Antibody Response and Variant Cross-Neutralization after SARS-CoV-2 Breakthrough Infection

Timothy A. Bates; Savannah K. McBride; Bradie Winders; Devin Schoen; Lydie Trautmann; Marcel E. Curlin; Fikadu G. Tafesse

doi:10.1001/jama.2021.22898

Antibody Response and Variant Cross-Neutralization after SARS-CoV-2 Breakthrough Infection

Timothy A. Bates, Savannah K. McBride, Bradie Winders, Devin Schoen, Lydie Trautmann, Marcel E. Curlin, Fikadu G. Tafesse

Research output: Contribution to journal › Letter › peer-review

69 Scopus citations

Original language	English (US)
Pages (from-to)	179-181
Number of pages	3
Journal	JAMA
Volume	327
Issue number	2
DOIs	https://doi.org/10.1001/jama.2021.22898
State	Published - Jan 11 2022

ASJC Scopus subject areas

General Medicine

Access to Document

10.1001/jama.2021.22898

Cite this

@article{4f91a89e00374052bdb735cf052479ba,

title = "Antibody Response and Variant Cross-Neutralization after SARS-CoV-2 Breakthrough Infection",

author = "Bates, {Timothy A.} and McBride, {Savannah K.} and Bradie Winders and Devin Schoen and Lydie Trautmann and Curlin, {Marcel E.} and Tafesse, {Fikadu G.}",

note = "Funding Information: Conflict of Interest Disclosures: Dr Reiss reported owning stock in GlaxoSmithKline and serving as an unpaid member of Moderna{\textquoteright}s advisory ethics committee. Dr Attwell is a member of the Australian Technical Advisory Group on Immunization COVID-19 working group 2 and is a current recipient of a Discovery Early Career Researcher Award funded by the Australian Research Council of the Australian government (DE19000158). No other disclosures were reported. Funding Information: Funding/Support: This study was funded in part by an unrestricted grant from the M. J. Murdock Charitable Trust, an unrestricted grant from the Oregon Health & Science University (OHSU) Foundation, National Institutes of Health training grant T32HL083808 on Multidisciplinary Research Training in Pulmonary Medicine, and OHSU Innovative IDEA grant 1018784.",

year = "2022",

month = jan,

day = "11",

doi = "10.1001/jama.2021.22898",

language = "English (US)",

volume = "327",

pages = "179--181",

journal = "JAMA",

issn = "0098-7484",

publisher = "American Medical Association",

number = "2",

}

TY - JOUR

T1 - Antibody Response and Variant Cross-Neutralization after SARS-CoV-2 Breakthrough Infection

AU - Bates, Timothy A.

AU - McBride, Savannah K.

AU - Winders, Bradie

AU - Schoen, Devin

AU - Trautmann, Lydie

AU - Curlin, Marcel E.

AU - Tafesse, Fikadu G.

N1 - Funding Information: Conflict of Interest Disclosures: Dr Reiss reported owning stock in GlaxoSmithKline and serving as an unpaid member of Moderna’s advisory ethics committee. Dr Attwell is a member of the Australian Technical Advisory Group on Immunization COVID-19 working group 2 and is a current recipient of a Discovery Early Career Researcher Award funded by the Australian Research Council of the Australian government (DE19000158). No other disclosures were reported. Funding Information: Funding/Support: This study was funded in part by an unrestricted grant from the M. J. Murdock Charitable Trust, an unrestricted grant from the Oregon Health & Science University (OHSU) Foundation, National Institutes of Health training grant T32HL083808 on Multidisciplinary Research Training in Pulmonary Medicine, and OHSU Innovative IDEA grant 1018784.

PY - 2022/1/11

Y1 - 2022/1/11

UR - http://www.scopus.com/inward/record.url?scp=85121530301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85121530301&partnerID=8YFLogxK

U2 - 10.1001/jama.2021.22898

DO - 10.1001/jama.2021.22898

M3 - Letter

C2 - 34914825

AN - SCOPUS:85121530301

SN - 0098-7484

VL - 327

SP - 179

EP - 181

JO - JAMA

JF - JAMA

IS - 2

ER -

Antibody Response and Variant Cross-Neutralization after SARS-CoV-2 Breakthrough Infection

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this